


# Legacy of Excellence in Real-World Evidence Generation at Arbor Research

## Who We Are

### Historical Leaders in Real-World Evidence (RWE)

Launched the multinational Dialysis Outcomes and Practice Patterns Study (DOPPS) in 1996

 Dynamic and nimble non-profit with a rich track record of using causal inference principles to reduce bias in real-world data analysis

Experts in study design, site identification, and investigator engagement, with contract research organization (CRO) capabilities

## What We Offer

### Support Throughout Clinical Development Life Cycle

Support randomized controlled trial (RCT) design and planning

Lead evidence generation and real-world effectiveness studies

### Data Analysis

Proficiency in data curation, linkage, and management as well as biostatistics and epidemiology


### Data Solutions

Access to and expertise with large public and private databases with opportunities for logistical/CRO support for custom prospective data collection

A unique global perspective to inform clinical practices, shape evidence-based guidelines and health policies worldwide, and ultimately improve patient outcomes

## Data Generation and Access

### Data Coordinating Center

- 25+ years experience coordinating the international DOPPS, a cohort of >100K hemodialysis patients across 20 countries, as well as PDOPPS and CKDopps
- CRO capabilities in diverse international settings
- PARADIGM—a chronic kidney disease associated pruritus (CKD-aP) treatment registry to evaluate real-world outcomes of Difelikefalin in hemodialysis patients 

### Electronic Health Record (EHR) Extraction and Curation

- Modernized cost-efficient alternative to large cohort studies
- US dialysis: Long-standing relationships with multiple US dialysis providers and EHR data vendors with rich granular data on labs, medications, and clinical outcomes
- US CKD: Innovative partnership with NANI, a large nephrology practice with a robust database of >45,000 patients across 75 CKD clinics

### Public Data Sources

- CMS claims: Includes Medicare-eligible patients in the US with and without CKD
- USRDS (United States Renal Data System): 300,000+ US dialysis patients with Medicare coverage
- Patient demographics, ICD-10 diagnoses and procedures, prescriptions, labs, hospitalizations, other dialysis related variables, and dialysis facility characteristics
- With years of [United States Renal Data System](#) leadership, Arbor Research has a unique understanding of this database tailored to dialysis

## Contact Us



Visit [www.ArborResearch.org](http://www.ArborResearch.org) to learn more about how Arbor Research can serve your RWE needs



[StrategicGrowth@arborresearch.org](mailto:StrategicGrowth@arborresearch.org)

# Legacy of Excellence in Real-World Evidence Generation at Arbor Research

## Transforming data into evidence: RWE across the spectrum of drug development

- **RCT planning:** Leverage observational data to clarify decision points and optimize design
- **Evidence generation:** Create a compelling case for unmet needs
- **Post Authorization Safety Studies (PASS):** Evaluate safety profiles for newly approved medications
- **Real world effectiveness / registry:** Understand medication utilization and performance in everyday clinical practice
- **Monitoring trends:** Stay up-to-date to understand management strategies and identify gaps in care
- **External control arm:** Identify active comparators embedded in a larger cohort study
- **Policy research:** Opportunities for natural experiments to understand the impact on practices and outcomes
- **Patient-reported outcomes (PROs):** Pioneers in developing and capturing PROs to better understand the patient perspective

## Research Output

The Arbor Research RWE team has published hundreds of peer-reviewed manuscripts in scientific journals, including over 300 papers utilizing [DOPPS data](#).

Deliverables can be defined flexibly depending on the nature of the project, timeline of clinical development, and funder interests. Recent examples of output dissemination include:

- Manuscript or research letter publications in peer-reviewed journals
- Abstract publications and presentations at scientific conferences
- Internal-facing reports or dashboards with data and recommendations to support strategy
- Curated analysis-ready databases
- Document preparation for regulatory review
- Virtual (webinars and podcasts) and face-to-face (conference symposia) presentations targeted to health care professionals, patients, policy makers, and researchers